



## BioLineRx to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York

August 29, 2016

TEL AVIV, Israel, August 29, 2016 /PRNewswire/ --

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 18<sup>th</sup> Annual Rodman & Renshaw Global Investment Conference at the Lotte New York Palace Hotel in New York City.

The BioLineRx presentation is scheduled to start at 3:50 p.m. EDT on Monday, September 12, 2016. A live audio webcast of the presentation will be available online at the investor page of the [Company's website](#). An archive of the event will also be available for those unable to listen live.

In addition, any investors attending the conference that wish to meet with Mr. Serlin for a one-on-one meeting should contact Lily Khaykina at [lk@rodmanevents.com](mailto:lk@rodmanevents.com).

### About BioLineRx

BioLineRx is a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's leading therapeutic candidates are: BL-8040, a cancer therapy platform, which has successfully completed a Phase 2a study for relapsed/refractory AML, is in the midst of a Phase 2b study as an AML consolidation treatment, and has recently initiated a Phase 2 study in stem cell mobilization for allogeneic transplantation; and BL-7010 for celiac disease and gluten sensitivity, which has successfully completed a Phase 1/2 study. In addition, BioLineRx has a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates, and has recently signed a collaboration agreement with MSD (known as Merck in the US and Canada) to run a Phase 2a study in pancreatic cancer using the combination of BL-8040 and Merck's KEYTRUDA®.

For additional information on BioLineRx, please visit the Company's website at <http://www.bioginerx.com>, where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on Facebook, Twitter, and LinkedIn.

### Contact:

PCG Advisory  
Vivian Cervantes  
Investor Relations  
+1-212-554-5482  
[vivian@pcgadvisory.com](mailto:vivian@pcgadvisory.com)

or

Tsipi Haitovsky  
Public Relations  
+972-3-624-0871  
[tsipihai5@gmail.com](mailto:tsipihai5@gmail.com)

SOURCE BioLineRx Ltd.